Skip to main content

Work in progress

Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change. 


Open consultations

We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views. 

We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.

Title: Understanding unlicensed medicines

Status: Consultation open - Closing date: 18 November 2022

Remit: This will provide guidance for prescribers across primary and secondary care settings, including clarification around what the different types of unlicensed medicines are, understanding responsibilities throughout the different stages of the prescribing journey and key steps to be taken when prescribing unlicensed medicines and transferring care of relevant patients.

Estimated publication date: December 2022-February 2023

Back to top


Medicines appraisals

Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.

Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.

We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.

Medicine name: levodopa/carbidopa/entacapone (Lecigon®)

Reference number: 4871

Indication: Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results

Patient and carer submission: Download form or submit online

Patient organisation submission: Download form or submit online

Clinical experts submission: Download form

Submission deadline: TBC

AWMSG meeting date: TBC

Back to top


Medicines optimisation projects

Title: All Wales chronic pain resources

Status: Consultation completed

Remit: Guidelines and resources developed to provide evidence based, prudently-driven guidance for the pharmacological management of chronic pain in Wales. In addition, quick reference guides, patient information leaflets, audit resources and educational materials will also be developed.

Estimated publication date: September-November 2022

Title: Polypharmacy review – guidance for prescribing (2022 update)

Status: Consultation completed

Remit: This will update and replace the existing ‘Polypharmacy: Guidance for prescribing’ document. The intention of this revision has been to focus the guidance on the groups of medicines commonly prescribed in the elderly population that may require review.

Estimated publication date: December 2022-February 2023

Title: Understanding unlicensed medicines

Status: Consultation open - Closing date: 18 November 2022

Remit: This will provide guidance for prescribers across primary and secondary care settings, including clarification around what the different types of unlicensed medicines are, understanding responsibilities throughout the different stages of the prescribing journey and key steps to be taken when prescribing unlicensed medicines and transferring care of relevant patients.

Estimated publication date: December 2022-February 2023

Back to top


One Wales Medicine assessments

One Wales Medicine new assessment

Medicine name: infliximab

Reference number: OW21

Indication: Treatment of patients with Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 31/10/2022

OWMAG date: November 2022

One Wales Medicine new assessment

Medicine name: vedolizumab (Entyvio®)

Reference number: OW22

Indication: Treatment of patients with Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 31/10/2022

OWMAG date: November 2022

One Wales Medicine new assessment

Medicine name: infliximab

Reference number: OW23

Indication: Treatment of pulmonary sarcoidosis refractory to standard treatments and when there are no pharmacological alternatives.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 30/11/2022

OWMAG date: December 2022

One Wales Medicine new assessment

Medicine name: vedolizumab (Entyvio®)

Reference number: OW24

Indication: Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children. 

  • Crohn's disease: following loss of response or non-response to anti-TNF and ustekinumab;
  • ulcerative colitis: following loss of response or non-response to anti-TNF treatment.

Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 30/11/2022

OWMAG date: December 2022

One Wales Medicine new assessment

Medicine name: ustekinumab (Stelara®)

Reference number: OW25

Indication: Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children. 

  • Crohn's disease: following loss of response or non-response to anti-TNF;
  • ulcerative colitis: following loss of response or non-response to anti-TNF and vedolizumab.

Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line.

Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk

Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk

Submission deadline: 30/11/2022

OWMAG date: December 2022

Back to top


Policies, strategies and other publications

 

Title: AWMSG annual report 2022-2023

Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2021 and March 2022.

Estimated publication date: September 2023

View previous AWMSG annual reports

Title: IPFR annual report 2021-2022

Summary: Review of Individual Patient Funding Request activity in Wales between April 2021 and March 2022. 

Estimated publication date: September 2022

View previous IPFR annual reports

Back to top

Follow AWTTC: